ArticleClinical and experimental nephrology2026
Clinical predictors of monoclonal gammopathy of renal significance: a multicenter study in Japan.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonoclonal gammopathy of renal significance (MGRS) results in kidney injury despite not meeting the hematological malignancy criteria necessitating treatment. Although kidney biopsy is crucial for diagnosis, it is an invasive procedure. Therefore, identifying patient characteristics associated with MGRS could aid in informing the decision to perform a biopsy.
methodsThis cross-sectional multicenter study included participants with monoclonal gammopathy (MG) who underwent kidney biopsy between 2018 and 2022. We excluded patients diagnosed with hematological malignancies requiring treatment or those with vasculitis. Patient factors associated with MGRS were evaluated using a logistic regression model. Additionally, we describe monoclonal protein-related kidney diseases associated with hematological malignancies.
resultsA total of 2972 kidney biopsies were performed, of which 166 (5.6%) were associated with MG. Among these 166 patients, 57 had hematological malignancies. Of the remaining 98 patients, excluding those with vasculitis, 44 (45%) exhibited MGRS lesions. Among the MGRS cases, 71% had amyloid light-chain amyloidosis, whereas nephrosclerosis and diabetic nephropathy were more common in non-MGRS cases. Multivariate analysis revealed that the clinical predictors associated with MGRS lesions were the presence of proteinuria ≥ 1.5 g/gCr, an abnormal free light chain (FLC) ratio, and the absence of diabetes. In hematological malignancy cases, monoclonal protein-related kidney diseases were observed in 49% of the cases, with kidney histology frequently exhibiting cast nephropathy or light chain deposition disease.
conclusionsAmong patients with MG who underwent kidney biopsy, 45% were diagnosed with MGRS. Predictors of MGRS included proteinuria ≥ 1.5 g/gCr, an abnormal FLC ratio, and the absence of diabetes.
Indexed as
Identifiers
40794252What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.